State Street Corp Lowers Position in MiMedx Group, Inc. (NASDAQ:MDXG)

State Street Corp reduced its position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 2.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,860,148 shares of the company’s stock after selling 107,819 shares during the period. State Street Corp owned approximately 2.63% of MiMedx Group worth $22,813,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in MDXG. Blue Trust Inc. purchased a new position in shares of MiMedx Group during the 3rd quarter worth approximately $30,000. Point72 Asset Management L.P. acquired a new position in MiMedx Group during the second quarter worth $40,000. Point72 DIFC Ltd raised its position in MiMedx Group by 127.6% in the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock worth $45,000 after acquiring an additional 4,275 shares in the last quarter. Entropy Technologies LP acquired a new stake in MiMedx Group in the third quarter valued at $64,000. Finally, Quest Partners LLC purchased a new stake in shares of MiMedx Group during the 2nd quarter worth $81,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Trading Up 0.2 %

Shares of MDXG stock opened at $9.10 on Monday. MiMedx Group, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $10.14. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The business has a fifty day simple moving average of $8.01 and a 200-day simple moving average of $7.09. The stock has a market cap of $1.34 billion, a P/E ratio of 16.55 and a beta of 1.98.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $12.00.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.